InMode Ltd. (NASDAQ:INMD) Receives Consensus Rating of “Hold” from Analysts

Shares of InMode Ltd. (NASDAQ:INMD) have been given an average rating of “Hold” by the six analysts that are currently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $32.80.

INMD has been the topic of several recent research reports. Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Tuesday, April 9th. Barclays dropped their target price on InMode from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, April 12th. Finally, UBS Group lifted their price target on InMode from $24.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, February 14th.

InMode Price Performance

Shares of NASDAQ:INMD opened at $17.14 on Friday. InMode has a 1 year low of $16.82 and a 1 year high of $48.25. The firm has a market capitalization of $1.44 billion, a PE ratio of 7.45 and a beta of 2.16. The business’s 50 day moving average price is $20.32 and its 200-day moving average price is $21.54.

InMode (NASDAQ:INMD) last released its earnings results on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $126.80 million during the quarter, compared to analyst estimates of $124.77 million. InMode had a net margin of 40.22% and a return on equity of 29.80%. The company’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.69 earnings per share. As a group, analysts expect that InMode will post 2.04 earnings per share for the current year.

Institutional Investors Weigh In On InMode

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Whalen Wealth Management Inc. grew its holdings in shares of InMode by 10.6% during the 1st quarter. Whalen Wealth Management Inc. now owns 10,378 shares of the healthcare company’s stock worth $224,000 after purchasing an additional 991 shares during the period. Kercheville Advisors LLC increased its position in shares of InMode by 2.7% during the first quarter. Kercheville Advisors LLC now owns 102,375 shares of the healthcare company’s stock valued at $2,212,000 after acquiring an additional 2,700 shares during the last quarter. Absher Wealth Management LLC increased its position in shares of InMode by 8.2% during the first quarter. Absher Wealth Management LLC now owns 29,531 shares of the healthcare company’s stock valued at $638,000 after acquiring an additional 2,231 shares during the last quarter. Kirr Marbach & Co. LLC IN raised its stake in shares of InMode by 3.4% in the 1st quarter. Kirr Marbach & Co. LLC IN now owns 92,541 shares of the healthcare company’s stock valued at $2,000,000 after acquiring an additional 3,079 shares during the period. Finally, Raymond James Financial Services Advisors Inc. lifted its holdings in shares of InMode by 74.3% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 98,089 shares of the healthcare company’s stock worth $2,120,000 after acquiring an additional 41,806 shares during the last quarter. Hedge funds and other institutional investors own 68.04% of the company’s stock.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.